Navigation Links
Nature Made(R) Liquid Softgels Presents American Idol's Kimberley Locke Live in Concert
Date:4/23/2008

Exclusive concert rocks National Women's Health Week and supports the

Society for Women's Health Research

NORTHRIDGE, Calif., April 23 /PRNewswire/ -- American Idol breakout star and Billboard chart-topper Kimberley Locke will perform a concert on May 15, 2008 in honor of National Women's Health Week. The exclusive event is sponsored by Nature Made Liquid Softgels, a new line of liquid softgels formulated for easy absorption and easy to swallow, in support of the Society for Women's Health Research, a national non-profit organization whose mission is to improve the health of all women through research, education and advocacy.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080423/LAW046-a)

(Logo: http://www.newscom.com/cgi-bin/prnh/20080423/LAW046LOGO-b)

This special one-hour event will take place at 2 p.m. at Nokia Theatre Times Square in New York City. Nearly 2,000 fans will be invited to commemorate National Women's Health Week with Locke and show their support for women's health awareness.

"I'm honored to partner with Nature Made in their support of the Society for Women's Health Research to inspire women across America to take control of their health," said singer Kimberley Locke. "As a woman who has triumphed over the challenges we all face in maintaining a healthy lifestyle, I encourage women to make a promise to invest in their own personal well-being." Locke famously shed 40 pounds by revamping her diet and participating in the VH1 series, "Celebrity Fit Club" to chronicle her weight loss journey and inspire others.

"As a company that understands the unique health needs of women with targeted solutions such as Liquid Softgels Multi for Her, Nature Made vitamins is thrilled to partner with Kimberley Locke and offer the public
'/>"/>

SOURCE Pharmavite
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Bioponic Phytoceuticals Announces Master Distributorship With Natures Best Covering 1,000 West Coast Retailers
2. Nature Made(R) Liquid Softgels Help Fuel Oprahs A New Earth Web Event
3. Nature Made(R) Changes the Way America Takes Vitamins
4. Natures helpers: Using microorganisms to remove TCE from water
5. 24 Hour Fitness Partners With Derek Jeter to Launch Signature Sports Clubs in New York City
6. Chemical signature of manic depression discovered by scientists
7. Breakthrough Acai Berry Anti-Aging Facial Applies Benefits of Natures Super-Food to the Skin
8. Avamere Health Systems Announces New President of Signature Home Health
9. Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross and Lifetime Television Deliver 20 Million Online Petition Signatures to Capitol Hill to Urge Congress to Stop Drive-Through Mastectomies
10. Iowa State University researchers work on gender, temperature link in reptiles published in Nature
11. Nature publication on pain research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...s the Latest Developments in Molecular,Testing and... /PRNewswire-USNewswire/ -- The practice of,pathol...g and the promise,of personalized medicine will ch...and other imaging technologies will change the way...ogists is taking a leadership role in,making sure ...
(Date:9/5/2008)...RNewswire-USNewswire/ -- The Health Resources,and ... million in grants to,increase and improve medical... grants continue President Bush,s historic expansi...w reach more economically,vulnerable and geographi...dministrator Elizabeth M. Duke said. "In 2007, mor...
(Date:9/5/2008)...tical ,anti-cloak, could bring objects out of hidi...-- Just in case someone develops a cloak of invisi... how to uncloak the objects it hides. , Accordi...in materials underneath an invisibility cloak woul...esearchers at Shanghai Jiao Tong University in Chi...
(Date:9/5/2008)...ain to commit to develop a National AIDS,Strategy ...p. 5 /PRNewswire-USNewswire/ -- The,Republican Nat...ion of the,domestic AIDS epidemic in the United St...erseas. Neither Presidential nominee Sen. John McC... mentioned AIDS in their remarks,to Convention del...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3
...rom constipation are more likely to get diagnosed ...ientists have little idea why this should be the c... may have some effect on the function of the gut l...re. Dr Robert Abbott, who led the research, said:...
...ts have no proven effectiveness in long-term weigh...those who adhere to them for more than a short tim...rt Associantion’s Nutrition Committee in Circulati...an Heart Association. Some of the diets increase f...
...unds commonly found in garlic may not only an effe...h they inhibit the infection appears to be similar...Researcher from the University of Toronto report t...ng of the American Society of Tropical Medicine an...
...ing the cholesterol drug simvastatin with the B vi...ther artery-disease complications by up to 90% in ...d heart arteries and low HDL (good) cholesterol sh... HDL levels, caused artery blockages to recede and...
Other Medicine News:Health News:High-protein diets may pose health risks 2Health News:Simvastatin Plus Niacin May Lower Heart Risks 2
(Date:9/4/2008)...trates potent antiviral activity and favorable saf...RIDGE, Mass., Sept. 4 /- Id...pharmaceutical company engaged,in the discovery an...viral,and other infectious diseases, today announc...y evaluating IDX899, a non-nucleoside reverse,tran...
(Date:9/3/2008)...stion Asked. Wrong Children Studied. Wrong,Conclus...ewswire/ -- A Centers for Disease,Control and Prev...no link,between the MMR vaccine and autism. The Na...es nothing to dispel the growing public concern ov...questions concerning design,and methodology., For...
(Date:9/3/2008)...s National Vascular Disease Awareness Month, CHAR...n Pharmaceuticals,LLC, a clinical-stage drug-devel...reatment of unmet medical needs, announced today t...I clinical trial of its lead drug,candidate trans ...T00725881,on the clinicaltrials.gov Website, is in...
(Date:9/3/2008)...ny to Discuss Phase 3 Plans with FDA, PRINCETON, ...Inc.,announced today that it successfully complet...he company,s new, innovative low-dose, once-weekly... by its internal product,code AG-200-15. The Phase...,primary endpoint of ovulation suppression, cycle ...
Breaking Medicine Technology:Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 2Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 3Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 4CDC Misses Target With Flawed MMR/Autism Study 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Factor key to severity of community associated methicillin resistant staph infections identified 6042 1Factor key to severity of community associated methicillin resistant staph infections identified 6042 2Factor key to severity of community associated methicillin resistant staph infections identified 6042 3Life threatening gene defect located by UT Houston researchers 1176 1Life threatening gene defect located by UT Houston researchers 1176 2Life threatening gene defect located by UT Houston researchers 1176 3Life threatening gene defect located by UT Houston researchers 1176 4Research suggests targeted treatment strategies for lupus 6037 1Research suggests targeted treatment strategies for lupus 6037 2Human clones 3A New U N analysis lays out worlds choices 1174 1Human clones 3A New U N analysis lays out worlds choices 1174 2Human clones 3A New U N analysis lays out worlds choices 1174 3Human clones 3A New U N analysis lays out worlds choices 1174 4
...ate breaking data,presented at the American Diabet...ns showed that, when used investigationally as,ini...tion with,metformin provided significant glycemic ...54 weeks in patients with type 2,diabetes. Additio...d also showed that JANUVIA significantly improved ...
...cant Clinical Results for,SB-509 in Development fo...22, 2007 /PRNewswire-FirstCall/ -- Sangamo,BioScie...ouraging,Phase 1 clinical data from its ZFP Therap...of the American Diabetes Association,(ADA). As dis...,Neurologic Exam and Nerve Conduction Velocities i...
Other Medicine Technology:Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 2Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 3Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 4Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 5Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 6Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 7Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 8Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 9Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 10Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 11Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 12Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 13Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 14Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 15Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 16Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 17Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 18Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 19Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 20Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 21Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 22Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 23Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 24Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 25Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 26Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 27Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 28Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 29Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 30Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 31Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 32Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 2Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 3Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 4Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 5
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
Medicine Products: